Best Cancer Specialist In Bangalore

Dr. Vijay Agarwal

Dr. Vijay Agarwal

best medical oncologist in bangalore

Dr. Vijay Agarwal

MD, MRCP, PhD, CCT

Lead and Senior Consultant - Medical Oncology and Haematology

Overview

Dr Vijay Agarwal is a medical oncologist specialising in the diagnosis and treatment of all types of cancers. Having delivered over 40000 chemotherapy, targeted therapy and immunotherapy, over 15 years he is one of the best medical oncologist and cancer specialist in Bangalore, India. He is the lead consultant and heads the department of Oncology for all Aster Hospitals in Bangalore. He uses the latest techniques, such as advanced imaging and molecular diagnostics, to come to a diagnosis quickly and efficiently. His cancer treatments are based on the latest treatment modalities, evidence and technology available depending upon his patient's needs, requirements and expectations. With a patient-centric approach and treatment delivered through a multi-disciplinary team, he strives to do the best for his patients.
He has trained extensively in United Kingdom (UK) and worked as a consultant in the UK before relocating to India in 2015. He has a keen interest in research following his PhD in Medicine in the UK. Has many peer reviewed publications in various international journals and is regularly invited to give talks and lectures by multiple organisations. 

Speciality: Medical Oncology (treatment of all types of cancers such as breast cancer, lung cancer, head and neck cancer, stomach cancer, colon cancer, prostate cancer, ovarian cancer, uterine cancer, cervical cancer, kidney cancer, liver cancer, sarcoma and brain tumours.
 

Qualifications

  • Certificate of Completion of Training (CCT) – Medical Oncology, General Medical Council, UK, 2012

  • PhD (Medical Sciences), Hull York Medical School, University of York, UK, 2012

  • Post Graduate Diploma in Research Training from Hull York Medical School, University of York, UK, 2011

  • Post Graduate Certificate in Clinical Education from Newcastle University, UK, 2008

  • MRCP (Medicine), Royal College of Physicians, UK, 2005

  • MD (General Medicine), Kasturba Medical College, Mangalore, India, 2002

  • MBBS, Jawaharlal Nehru Medical College, Belgaum, India, 1999

 

Work Experience

Dr Vijay Agarwal has a vast experience in the field of oncology and treats all types of cancers using chemotherapy, hormone therapy, targeted therapy and immunotherapy. He is currently the Lead and Senior Consultant at Aster CMI and Aster RV Hospitals and heads the cancer centres of all Aster hospitals in Bangalore and is supported by a team of doctors, nurses and various support staff. Previously he has worked at various hospitals in India and UK. His most recent previous appointments were

Senior Consultant Medical Oncologist; Health Care Global Enterprises, K. R. Road, Bangalore (2015 - 2018)
Consultant Medical Oncologist; Queen Elizabeth Hospital, University Hospital Birmingham NHS Trust, Birmingham, UK (2013 - 2015)

Awards & Recognitions

Vijay Agarwal, Beaumont KL, Campbell A, Lind MJ, Cawkwell L, Expression of PTEN in malignant pleural mesothelioma. Lung Cancer, 2011. 71(Supplement 1): p. S19. Poster - 9th Annual British Thoracic Oncology Group Conference, Dublin (January 2011). Awarded the best poster award for 2011.

 

Publications

  • Richa D. Jain, Mallikarjun Sakpal, Sonal Asthan, Mythri Shankar, Vijay Agarwal, Vidya MN, Nijalingappa Panchal, Karthik Raichurkar, Sudhir Kale. Primary hepatic neuroendocrine tumor: A rare entity. Radiol Case Rep. 2020;15(11):2362-2366.
  • Oguh-Olayinka L, Vijay Agarwal, Ranatunge D, Campbell A, Laufer S, Cawkwell L, Lind MJ. The investigation of Lipoxygenase as Therapeutic Targets in Malignant Pleural Mesothelioma. Pathol. Oncol. Res. (2019). https://doi.org/10.1007/s12253-019-00652-x
  • Vijay Agarwal, Anand Subash, Ravi C Nayar, Vishal Rao. Is EGFR really a therapeutic target in head and neck cancers? Journal of surgical oncology 2019;119(6):685-686
  • Sudeep Gupta, Sanjoy Chatterjee, Jagdish Nigade, Shyam Aggarwal, Manish Singhal, Alurkar S S, Anil Kukreja, Smruti B K, Shona Nag, Amit Agarwal, Vijay Agarwal, Chacko R T, Chirag Desai, Chanchal Goswami, PavithranKeechilat, Poonam Patil, Krishna Prasad, RejivRajendranath, Rao R R, Sahoo TP, Ashish Singh, Randeep Singh, Sankar Srinivasan, Arun Warrier, Binay Swarup, Priyanka Bhattacharya, Advani S H. Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective. Indian J Med Paediatr Oncol 2018;39(3):386-379
  • Nayar RC, Vijay Agarwal, Rao V, Sheela M L, Krishnamurthy N, Ghosh M. Human epidermal growth factor receptor-2 expression in head and neck squamous cell carcinoma: A potential for targeted therapy?. J Head Neck Physicians Surg 2016;4:85-6 
  • Chatterjee, M., Chinder, P., Mannan, A.U., Sheela, M.L., Mukherjee, U., Choudhury, S., Lo, C., Singh, S., Singh, J., Hazarika, D. and Prabhudesai, S., Gupta V., Kunigal SS., Swamy SK., Vijay Agarwal, Kumar A., and Ghosh M. Genotype-Phenotype Analysis in an Indian Family Affected with Li-Fraumeni Syndrome-Role of Genetic Counselling. International journal of human genetics, 2016;16(3-4): 98-106. 
  • Garimella V, Hussain T, Vijay Agarwal, Radhakrishna S, Fox JN, Kneeshaw PJ, Long ED, Mahapatra TK, McManus PL, Lind MJ, Drew PJ, Cawkwell L. Clinical response to primary Letrozole therapy in elderly patients with early breast cancer: Possible role for p53 as a biomarker. Int J Surg. 2014; 12(8):821-826
  • Vijay Agarwal, V C Hodgkinson, G L Eagle, L Scaife, M J Lind, Cawkwell L, Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. Int J Oncol. 2013; 42(3):1088-92
  • Vijay Agarwal, Campbell A, Beaumont KL, et al.: PTEN protein expression in malignant pleural mesothelioma. Tumour Biol, 2013;34(2):847-51
  • V C Hodgkinson, Vijay Agarwal, D ELFadl, J N Fox, P L McManus, T K Mahapatra, P J Kneeshaw, P J Drew, M J Lind, Cawkwell L, Pilot and feasibility study: comparative proteomic analysis by 2-DE
  • MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics.2012.17;75(9):2745-52. [IF 4.8]
  • V C Hodgkinson, D ELFadl, Vijay Agarwal, V Garimella, C Russell, E D Long, J N Fox, P L McManus, T K Mahapatra, P J Kneeshaw, P J Drew, M J Lind, Cawkwell L, Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? Journal of Proteomics, 2012. 75: 1276-1283. [IF 4.8]
  • Vijay Agarwal, V., M.J. Lind, and L. Cawkwell, Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand? Cancer Treat Rev, 2011. 37(7): p. 533-42. [IF 6.0]
  • Vijay Agarwal, P. Oneill. Adjuvant! Online as a Decision-making Tool in Early Breast Cancer — a UK National Survey. Clinical Oncology (R Coll Radiol), 2011. 23(2): 159-160. [IF 2.0]
  • Vijay Agarwal, Wah T, Chilka S, Joffe J, Stark D. Urethral metastasis from non-seminomatous germ cell tumour in a 35-year-old man: a case report. J Med Case Reports, 2011. 5(1): p. 12.
  • Vijay Agarwal, R. Prasad, and M. Butt. Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer. Clinical Medicine Insights: Therapeutics, 2009. (CMT-1-Agarwal-et-al): p. 715.
  • Vijay Agarwal, Sgouros J, Smithson J, Lodge J P A, Razack A, Campbell A, Maraveyas A. Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. J Med Case Reports. 2008; 2: 227.

Posters and Presentations:

  • Vijay Agarwal, R. Rao, H.R. Abin, V. Rao, R.C. Nayar, V. Mani, A. Ram, BS. Ajaikumar. Pre-treatment neutrophil-lymphocyte ratio/platelet lymphocyte ratio as surrogate markers of survival in non-metastatic head and neck cancer patients: An observational study. Annals of Oncology 28 (Supplement 5): v543–v567, 2017
  • T Middle, M Loveday, N Pettitt, Vijay Agarwal. Education - Integral part of adult Tumour of Young Adolescents services? Poster B121, NCRI, Liverpool, UK (2012)
  • Vijay Agarwal, Brendan O'Sullivan, Phillipe Taniere, M J Lind, L Cawkwell. Overcoming resistance to EGFR pathway inhibition in mesothelioma cells. Poster - The 11th International Conference of the International Mesothelioma Interest Group, Boston, USA (September 2012)
  • Hussain T, Vijay Agarwal, Garimella V, Radhakrishna S, Fox JN, Kneeshaw PJ, Long ED, Mahapatra TK, McManus PL, Lind MJ, Drew PJ, Cawkwell L. Clinical response to primary Letrozole therapy in women over 70 years with early breast cancer: A retrospective study with a five-year follow-up. European Journal of Surgical Oncology EJSO 38(5): 433 (2012). Poster - Association of Breast Surgery Conference, Bournemouth (May 2012)
  • Vijay Agarwal, Lind MJ, Cawkwell L (2012) Inhibition of EGFR, MTOR and COX pathways in mesothelioma cells. Lung Cancer 75: S22 (abstract). Poster - 10th Annual British Thoracic Oncology Group Conference, Dublin (January 2012) 
  • Vijay Agarwal, M.J. Lind, and L. Cawkwell, 1158 POSTER Inhibition of Epidermal Growth Factor Receptor in Malignant Pleural Mesothelioma. European Journal of Cancer (1990), 2011. 47: p. S141. ECCO 17 - 36th ESMO Multidisciplinary Congress, Stockholm (September 2011)
  • Vijay Agarwal, M.J. Lind, and L. Cawkwell, 1157 POSTER Growth Inhibition of Mammalian Target of Rapamycin (MTOR) in Malignant Pleural Mesothelioma. European Journal of Cancer (1990), 2011. 47: p. S140-S141. ECCO 17 - 36th ESMO Multidisciplinary Congress, Stockholm (September 2011)
  • Vijay Agarwal, D. Ranatunge, K. Beaumont, A. Campbell, M. J. Lind, L. Cawkwell. Putative biomarkers in malignant pleural mesothelioma. J Clin Oncol 29: 2011 (suppl; abstract e21008)
  • Vijay Agarwal, Hodgkinson VC, Eagle GL, Scaife L, Lind MJ, Cawkwell L. Proteomic analysis of the mechanism of action of a COX2 inhibitor (DuP-697) in mesothelioma. Lung Cancer, 2011. 71(Supplement 1): p. S17. Poster - 9th Annual British Thoracic Oncology Group Conference, Dublin (January 2011) 
  • Vijay Agarwal, Ranatunge D, Campbell A, Lind MJ, Cawkwell L. Expression of 5 & 12 Lipoxygenase in malignant pleural mesothelioma. Lung Cancer, 2011. 71(Supplement 1): p. S19. Poster - 9th Annual British Thoracic Oncology Group Conference, Dublin (January 2011) 
  • Vijay Agarwal, Beaumont KL, Campbell A, Lind MJ, Cawkwell L, Expression of PTEN in malignant pleural mesothelioma. Lung Cancer, 2011. 71(Supplement 1): p. S19. Poster - 9th Annual British Thoracic Oncology Group Conference, Dublin (January 2011). 
  • Vijay Agarwal, D Ranatunge, A Campbell, M J Lind, L Cawkwell. Analysis of lipoxygenase pathways in malignant pleural mesothelioma. Poster - The 10th International Conference of the International Mesothelioma Interest Group, Kyoto, Japan (Aug 2010)
  • Vijay Agarwal. and P. O'Neill. UK national survey on the use of Adjuvantonline as a decision-making tool in early breast cancer (www.adjuvantonline.com) European Journal of Cancer Supplements, 2009. 7(2): p. 318. Poster - ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin (September 2009)
  • Hodgkinson VC, ELFadl D, Vijay Agarwal, Garimella V, Drew PJ, Lind MJ, LC: Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 and BID? Cancer Research 2011, 71(24):555s (abstract P555-513-515). Poster - San Antonio Breast Cancer Symposium, USA (Dec 2011)
  • Elmahdawi N, Graham L, Gupta S, Sadia H, Vijay Agarwal, Butt M. Prospective observational study of the proportion hospitalised cancer patients at risk of refeeding syndrome. European Journal of Cancer Supplements, September 2009. 7(3): p. 24 (58LBA). Poster - ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin (September 2009)

Oral Presentations:

  • R. Rao, N. Saha, V. Mani, R. Amritanshu, R. Geetha, N. Radheshyam, S. Patil, H.P. Shashidhara, T.C. Satheesh, V. Agarwal, BS. Ajaikumar. Pre-chemotherapy nutritional status and chemotherapy response: An observational study Annals of Oncology 28 (Supplement 5): v543–v567, 2017. European Society of Medical Oncology Congress (Sept 2017, Madrid). Presenting author V. Agarwal.
  • Proteomic analysis of the mechanism of action of DuP-697 in mesothelioma cells. The 10th International Conference of the International Mesothelioma Interest Group (Aug 2010, Japan)

Dissertations and Thesis:

  • The significance of the EGFR pathway in Malignant Pleural Mesothelioma. Accepted by Hull York Medical School, UK, for the award of PhD (2013). 
  • Measurement of left ventricular mass index by echocardiography and its correlation with current electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in hypertensive patients. Accepted by Manipal Academy of Higher Education, India, for the award of MD (2002).

Media and blogs

  • Suraksha P. ‘Cancer patients make surprising full recovery from Covid-19’ Deccan Herald 7 Sept 2020. www.deccanherald.com
  • Kumaran P. ‘Cancer patients must tele-consult with docs’ Bangalore Mirror. 9 April 2020. bangaloremirror.indiatimes
  • Vijay Agarwal. 'Commitment to tame the disease and increasing awareness can make India cancer-free.' Punediary.com 5 Feb 2019. punediary.com

  • Chetana Belagere. 'Cancer cure in sight, claims firm, but experts unsure.' The New Indian Express 4 Feb 2019. newindianexpress.com

  • Vijay Agarwal. 'World Cancer Day: Immunotherapy can help patients suffering from carcinoma of the lungs.' The Economic Times 4 Feb 2019. economictimes.indiatimes

  • Vijay Agarwal, Aditya Murali. 'Yes, it can be diagnosed AND treated while you're carrying.' Mother & Baby 15 December 2018. www.pressreader.com

  • Nimeshika Jayachandran,Geetika Mantri. 'Lung cancer in non-smokers on the rise: What does this mean?' The NEWS Minute 25 August 2018. thenewsminute.com

  • Vijay Agarwal. 'Cancers occur in the bones account for less than 1% of all cancers.' HealthySoch 21 July 2018. www.healthysoch.com

  • Vijay Agarwal. 'One per cent of call cancers are sarcomas.' The New Indian Express 19 July 2018. newindianexprss.com

  • Vijay Agarwal. 'Merck presents Let's March Ahead & Unite Against Colorectal Cancer.' Times Influence 2 April 2018.  www.youtube.com

  • Vijay Agarwal. 'Colorectal cancer on the rise due to unhealthy diet.' The New Indian Express 29 March 2018. newindianexpress.com

  • Vijay Agarwal. 'Today we can augment the body's immune system to attack cancer cells.' ETHealthWorld 15 Dec 2017. Accessed on 12 March 2018. economictimes

  • Vijay Agarwal. 'Smoking: A proven risk factor for smoking.' THEWEEK. 31 November 2017. 

  • Vijay Agarwal. 'Personalised cancer treatment- revolutionising the cancer scenario in India.' Business Economics 31 August 2017. Accessed on 12 March 2018. businesseconomics.in

  • Kaniza Garari. 'For Indian cancer patients, immunotherapy is way pricey.' Deccan Chronicle 28 July 2017. Accessed on 12 March 2018. www.deccanchronicle.com

Related Blogs

Testimonials